In ovarian cancer, EMP1 is frequently upregulated, especially in advanced and chemoresistant cases, and high EMP1 expression is associated with poor prognosis, advanced stage, metastasis, and cisplatin resistance [120,122,123,124]. This evidence concerns the gene EMP1 and ovarian carcinoma.